International Stem Cell Corporation

Equities

ISCO

US4603782016

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 10:45:04 2024-04-24 am EDT			5-day change	1st Jan Change
0.065 ^USD	-8.71%		-8.71%	+4.84%

Mar. 28	International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2021

March 29, 2022 at 04:35 pm EDT

International Stem Cell Corporation reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 0.899 million compared to USD 2.72 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.36 a year ago.

Latest news about International Stem Cell Corporation

International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
International Stem Cell Corporation and Dr. Andrey Semechkin Agrees to Extend (Until September 15, 2024) the Maturity Date of the Loan	23-09-18	CI
Bayer says Parkinson's stem cell therapy improves symptoms in initial trial	23-08-28	RE
International Stem Cell Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Bayer claims early lead in Parkinson's stem cell therapy	23-06-28	RE
International Stem Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
International Stem Cell Corporation Auditor Raises 'Going Concern' Doubt	23-03-29	CI
International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
International Stem Cell Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
International Stem Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Earnings Flash (ISCO) INTERNATIONAL STEM CELL CORPORATION Reports Q4 Loss $-0.11	22-03-30	MT
International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-29	CI
International Stem Cell Corporation Auditor Raises 'Going Concern' Doubt	22-03-28	CI
International Stem Cell Corporation Announces Resignation of Sophia Garnette as Principal Financial Officer and VP of Legal Affairs and Operations, Effective April 1, 2022	22-02-02	CI
International Stem Cell Corporation announced that it has received $0.25 million in funding	22-01-12	CI
International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
International Stem Cell Corporation and S Real Estate Holdings, Llc Enters into Lease Agreement with Rehco Holdings	21-11-01	CI
International Stem Cell Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-13	CI
International Stem Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-14	CI
International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-30	CI
International Stem Cell Corporation announced that it has received $0.35 million in funding	21-03-04	CI
International Stem Cell Corporation and Dr. Andrey Semechkin Agreed to Extend Maturity Date of the Loan Until January 15, 2022	21-01-19	CI
International Stem Cell Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-12	CI

Chart International Stem Cell Corporation

Duration

Period

Chart International Stem Cell Corporation

More charts

Company Profile

International Stem Cell Corporation is a clinical-stage biotechnology company that is focused on therapeutic and biomedical product development. The Company is primarily a research and development company, for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The Company's products are based on human cell culture and a type of pluripotent stem cells and hpSCs. The Company's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INTERNATIONAL STEM CELL CORPORATION	+4.84%	520K
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+46.23%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research